Platelet

ProPhase Labs Announces Significant Laboratory Expansion

Retrieved on: 
Lundi, juin 13, 2022
DNA sequencing, NGS, TK, Whole genome sequencing, Company, Hemostasis, Research, Marketing, Food, Genetic, Immunoassay, OTC, Hematology, Platelet, Genetics, CLIA, RNA, Environment, Nebula Genomics, Failure, COVID-19 testing, Nasdaq, Gene, Urine test strip, Physician, GLOBE, FDM, Bleeding time, Private Securities Litigation Reform Act, RT-PCR, DNA, Laboratory, Media relations, PCR, COVID-19, Prothrombin time, Risk, Prophase, Chromosome, Acquisition, NASDAQ, SEC, Severe acute respiratory syndrome coronavirus 2, Institution, Inherited disorders of trafficking, Heart, Thromboplastin, Dietary supplement, Genomics, WGS, University, Antibiotics, Pharmaceutical industry, Blood product, Vaccine

Garden City, NY, June 13, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it has partnered with world-renowned healthcare diagnostics innovators for new clinical chemistry, immunoassay, hematology, hemostasis and urinalysis analyzers as part of its plan to significantly expand its in-house clinical testing capabilities. State-of-the-art clinical testing equipment has been procured and a new lease executed for additional space at the company’s corporate headquarters in Garden City, New York. Plans are also under way to expand the company’s in-house genomics testing offerings.

Key Points: 
  • ProPhase Labs relocated to its current headquarters in January 2021 and built from scratch a 25,000 square foot state-of-the-art CLIA certified laboratory to support the companys growing COVID-19 testing franchise.
  • Ted Karkus, ProPhase Labs Chief Executive Officer, commented, We are very excited to broaden ProPhases testing capabilities at our Garden City headquarters.
  • ProPhase Diagnostics, Inc. (ProPhase Diagnostics), a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19).
  • ProPhase Precision Medicine, Inc. (ProPhase Medicine), a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022

Retrieved on: 
Vendredi, juin 10, 2022
Congress, Ruxolitinib, Plasma, Dysgeusia, Sale, COVID-19, Omicron, European Medicines Agency, Cancer, Șaeș, MPL, ELN, Lymphatic system, Pancreatic serous cystadenoma, Ageing, CEO, Bleeding, Lists of disasters, ET, Arthralgia, MF, Blood, Trial of the century, Bone marrow, Essential thrombocythemia, AES, EMA, Priority, Annual report, Webcast, TSS, Patient, Fast Track, JAK2, Compliance, EHA, Mutation, Private Securities Litigation Reform Act, Constipation, LSD1, Facebook, Society, Fatigue, ASH, LinkedIn, Platelet, MPN, FDA, Growth, GLOBE, Risk, Pandemic, Causality, SAN, CALR, Safety, Pharmaceutical industry, Residential care, Bottled water, Medical imaging, Imago

The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA) taking place 9-12 June 2022.

Key Points: 
  • The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA) taking place 9-12 June 2022.
  • Of the 31 patients with Total Symptom Score (TSS) data available at 24 weeks:
    58% (18/31) showed a decrease in TSS.
  • I am genuinely thrilled with the results of our ongoing Phase 2 clinical study of bomedemstat in essential thrombocythemia (ET) that continues to support the tremendous potential of our drug candidate.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia ( NCT04254978 ) and myelofibrosis ( NCT03136185 ).

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Vendredi, mai 27, 2022
Employment, Ruxolitinib, Company, CTI, Patient, NASDAQ, Financial compensation, CTIC, Galena Biopharma, Platelet, FDA, Thrombocytopenia, Board, JAK2, Vera, Acquisition, JAK1, Pharmaceutical industry, Amend

The equity awards were approved on May 27, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved on May 27, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received options to purchase an aggregate of 94,000 shares of CTI BioPharma common stock.
  • One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates.
  • VONJO is a trademark of CTI BioPharma Corp.

Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Jeudi, mai 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, Ruxolitinib, Thrombocytopenia, Risk, Disease, European Society for Medical Oncology, Nausea, Private Securities Litigation Reform Act, Annual general meeting, Oncology, U.S. Securities and Exchange Commission, SRR, NCCN, MMB, Danazol, 2021 Essex County Council election, Patient, NASDAQ, TSS, Itch, Society, Platelet, Weakness, Week, Program, Momelotinib, Anemia, Safety, ASCO, DAN, National Comprehensive Cancer Network, Security (finance), ESMO, Diarrhea, Pharmaceutical industry, Medical imaging, Medicine, MD

An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for an oral presentation on June 7.

Key Points: 
  • An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for an oral presentation on June 7.
  • Receiving an oral presentation at ASCO for our pivotal Phase 3 study datawhich demonstrated that momelotinib achieved statistically significant and clinically important efficacy across all prespecified and key secondary endpointsis truly a momentous occasion for Sierra Oncology.
  • The primary and all key secondary results, as well as safety data, from the MOMENTUM pivotal Phase 3 trial of momelotinib will be presented in an oral presentation by Ruben Mesa, MD, co-Principal Investigator of the study.
  • Serious treatment emergent adverse events were 35% in the MMB arm and 40% in the control arm.

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Retrieved on: 
Mardi, mai 24, 2022
People, CLR, Severe acute respiratory syndrome coronavirus 2, Platelet, Risk, Death, Shock, Organ dysfunction, Autoimmune hemolytic anemia, Thermoregulation, Waiha, Patient, Common, Antibody, Macrovascular disease, GUD, AIHA, Endothelial dysfunction, Therapy, Macrophage, Nature, COVID-19, Jean-Louis Vincent, TSX, Bruise, Intention, Infection, Partnership, Bleeding, ITP, SYK, Splenectomy, Pathology, Neutrophil extracellular traps, Acute kidney injury, Neutrophil, NETS, Monocyte, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), Immune system, Steroid, Knight Therapeutics, Fostamatinib, CEO, Annual report, GLOBE, Pharmaceutical industry, Vaccine, Generic drug, Rigel, Uniting Medically Supervised Injecting Centre, Knight

MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Key Points: 
  • MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • In return, Knight receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America.
  • We are excited to be working with Rigel to provide access to an innovative, first-in-class treatment option to patients across Latin America with chronic ITP.
  • TAVALISSE and TAVLESSE are registered trademarks of Rigel Pharmaceuticals, Inc.
    Investor Contact for Knight Therapeutics Inc.:

PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

Retrieved on: 
Vendredi, mai 13, 2022
Risk, Income, Company, Pain, Sales, Platelet, DAPT, Private Securities Litigation Reform Act, Research, Aspirin, Patient, Mission statement, NASDAQ, Franchi, Nielsen, Corporate communication, Review, SKU, API, Investor relations, Stomach, DRS, Awareness, Failure, Marketing, FDA, Patent, University, Pharmacokinetics, Industry, National Heart Foundation of Australia, Net, Conference, Intellectual property, OBI Pharma, Inc., Manuscript, Comparative advertising, Adoption, PLX, GAAP, Pharmacodynamics, Fortis Healthcare, SEC, Absorption, CEO, HCPS, GLOBE, Video game, Bank, Generic drug, Management, Pharmaceutical industry, Medical device, Aluminium

SPARTA, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), announced today certain financial and operational results for the three months ended March 31, 2022.

Key Points: 
  • A manuscript of recently reported pharmacokinetic/pharmacodynamic results on VAZALORE 81 mg has been submitted to a journal for publication and is under review.
  • Total revenues for the first quarter of 2022 were $2.1 million, compared to no revenue in the first quarter of 2021.
  • Research and development expenses declined approximately 32% to $0.7 million in the first quarter of 2022, compared to approximately $1 million in first quarter of 2021.
  • These forward-looking statements represent PLxs estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.

CTI BioPharma Reports First Quarter 2022 Financial Results

Retrieved on: 
Jeudi, mai 12, 2022
Ruxolitinib, Company, NCCN, Nasdaq, CTI, Patient, CTIC, Galena Biopharma, Marketing, Platelet, FDA, JAK, National Comprehensive Cancer Network, Vera, Acquisition, Myeloproliferative neoplasm, Pharmaceutical industry

ET

Key Points: 
  • ET
    SEATTLE, May 12, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2022.
  • ET)
    Net product sales of $2.3 million for the first quarter ended March 31, 2022 were attributable to VONJO product sales in the United States.
  • CTI will host a conference call and webcast to review its first quarter 2022 financial results and provide an update on business activities today, May 12 at 4:30 p.m.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

Retrieved on: 
Jeudi, mai 12, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Ruxolitinib, Spleen, SRR, MMB, Doctor of Philosophy, 2021 Essex County Council election, Patient, European Hematology Association, NASDAQ, TSS, Â, Platelet, EHA, Program, Momelotinib, Anemia, Safety, MD, Pharmaceutical industry, Medical imaging, Weapon

An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation.

Key Points: 
  • An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation.
  • Additionally, a subset analysis from the trial evaluating safety and efficacy for patients with low platelet counts has been selected for poster presentation.
  • The data to be presented further expand upon the potential of momelotinib as a treatment option for myelofibrosis patients who are symptomatic and anemic.
  • The primary and all key secondary results, as well as safety data, from the MOMENTUM pivotal Phase 3 trial of momelotinib will be presented in an oral presentation by Srdan Verstovsek, MD, PhD, co-Principal Investigator of the study.

CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Mardi, mai 10, 2022
Janus, Thrombocytopenia, ASCO, Cytokine, Pacritinib, TYK2, Nasdaq, Haematopoiesis, CSF1R, JAK2, Company, JAK3, JAK1, FMS, Primary myelofibrosis, Patient, Vera, American Society of Clinical Oncology, FDA, CTI, Ruxolitinib, Society, CTIC, CD135, FLT3, Annual general meeting, Acquisition, Platelet, Pharmaceutical industry

SEATTLE, May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021.

Key Points: 
  • SEATTLE, May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021.
  • Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • VONJOTM is a trademark of CTI BioPharma Corp.

Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range

Retrieved on: 
Jeudi, mai 5, 2022
Medical Supplies, Medical Devices, Health, Other Health, General Health, Biotechnology, COVID-19, U.S. Securities and Exchange Commission, Investment, Mission statement, IFC, GAAP, Adjustment, EMEA, EBITDA, Fresenius (company), Company, Plasma, Safety, Bleeding, Red blood cell, Â, Patient, BLA, Depreciation, Security (finance), Risk, FDA, SG, LifeSouth Community Blood Centers, Platelet, Annual report, Hospital, Transfusion medicine, Government, R, Licensure, Income, LinkedIn, SEC, American Red Cross, Research, Factor, Growth, World Red Cross and Red Crescent Day, Investor relations, PAS, Animal, Blood product, Bank, Cryptocurrency, Pharmaceutical industry, Renewable energy, Video game, Online gambling, Online shopping, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Cryoprecipitate

With the visibility we have for another year of robust demand for INTERCEPT products, we have opted to raise our product revenue guidance range for 2022.

Key Points: 
  • With the visibility we have for another year of robust demand for INTERCEPT products, we have opted to raise our product revenue guidance range for 2022.
  • Product revenue during the first quarter of 2022 was $37.4 million, compared to $23.4 million during the prior year period.
  • First quarter 2022 government contract revenue was $5.6 million, compared to $6.2 million during the prior year period.
  • The Company expects full-year 2022 product revenue will be in the range of $160-165 million, representing strong growth of approximately 22%-26% compared to full-year 2021 product revenue of $130.9 million.